FDA warning drives doubts on Epogen drug

A Food and Drug Administration warning about the use of antianemia drugs is increasing pressure on Medicare officials to change payment policies for Amgen Inc.'s Epogen, which accounts for $2 billion in federal kidney-dialysis reimbursements. (Full article: 951 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

• $4.95 1 article
• $9.95 4 articles
• $25.95 Monthly